![]() ![]() Inappropriate shocks occurred in 35 patients through all follow-ups, with a rate of 10.2% at one year. This predominantly relates to the lead-anchoring technique. It observed the most common major complication, lead dislodgement (10 events in nine patients), at zero to 120 days post-implant. Medtronic observed a 91.9% rate of freedom from major EV ICD system- or procedure-related complications through 18 months. Data built on the EV ICD’s previously reported defibrillation effectiveness results at implant (98.7%). Patients avoided shocks in nearly half of all spontaneous episodes because of the availability of ATP, Medtronic said. ![]() Medtronic said that of discrete episodes treated with shock, 21 of 21 were successfully terminated.ĪTP successfully treated 35 of 52 episodes (67.3%). Nineteen patients experienced 80 spontaneous, appropriately treated arrhythmic episodes. The company presented data as late-breaking science at Heart Rhythm 2023.Īn estimated 6.8% of patients experienced the appropriate therapy by 18 months. Medtronic’s EV ICD pivotal study for safety and effectiveness followed 299 implanted patients through an average of 17.1 months. The ICD offers anti-tachycardia pacing (ATP) and pause prevention pacing. Using a minimally invasive approach, the implant goes below the left armpit in the left mid-axillary region. It designed the system with a lead placed outside the heart and veins, under the sternum. Medtronic’s first-of-its-kind implantable defibrillator aims to avoid certain risks of traditional, transvenous ICDs. The medtech giant designed its extravascular (EV) ICD system to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. Medtronic (NYSE:MDT) announced positive long-term follow-up results for its investigational implantable cardioverter defibrillator (ICD). Philips said novel AI models “lay the foundation for a new approach to cardiac risk management.” The company believes it can apply across multiple care settings, helping to identify at-risk patients earlier. The model correctly predicted VT occurrence in 88% of Holter users with rapid VT. On the external validation dataset, sensitivity and specificity came in at 78.9% and 81.4%, respectively. The model achieved a sensitivity of 83.3% and a specificity of 88.7% on its internal validation dataset. The study evaluated a two-week period using data from the first 24 hours of monitoring. Researchers studied the algorithm’s ability to predict the risk of sustained VT (lasting longer than 30 seconds). The model then retrospectively validated the model using retrospective 14-day ambulatory ECG recordings from 2019 to 2023. The AI-based learning model used a deep neural network and 115,505 ambulatory ECG recordings gathered from independent diagnostic testing facilities in five countries. It successfully predicted sustained ventricular tachycardia (VT) over a two-week period when compared to ambulatory ECG data. The study, “Near-Term Prediction of Life-Threatening Ventricular Arrhythmias using Artificial Intelligence-Enabled Single Lead Ambulatory ECG,” used an AI-based learning model. Philips (NYSE:PHG) presented data demonstrating how artificial intelligence (AI) can help predict life-threatening ventricular arrhythmias. Here’s a roundup of Associate Editor Sean Whooley’s reporting on news out of Heart Rhythm 2023: Stay tuned as we delve deeper into the details of these groundbreaking technologies and their impact on the field of cardiology. As these innovations continue to advance, they have the potential to significantly improve the lives of patients worldwide. The cardiology devices showcased at the Heart Rhythm 2023 hold promise for the future of cardiovascular care. The innovations presented during the event offer new avenues for diagnosis, treatment, and monitoring of cardiovascular conditions, providing hope for patients worldwide.īoston Scientific, Abbott, Medtronic, Philips, and iRhythm unveiled advances that have the potential to revolutionize the field of cardiology and improve patient outcomes. Medical device companies showcased groundbreaking technologies at Heart Rhythm 2023, May 19-21 in New Orleans. The future of cardiac care was on display at the Heart Rhythm Society’s 2023 annual meeting. ![]()
0 Comments
Leave a Reply. |